KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Shares Outstanding (Diluted Average) (2019 - 2025)

Rigel Pharmaceuticals has reported Shares Outstanding (Diluted Average) over the past 10 years, most recently at $18.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 6.52% year-over-year to $18.8 million; the TTM value through Dec 2025 reached $18.8 million, up 6.52%, while the annual FY2025 figure was $18.8 million, 6.52% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $18.8 million at Rigel Pharmaceuticals, down from $19.2 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $176.5 million in Q3 2021 and troughed at $17.0 million in Q4 2022.
  • A 5-year average of $80.2 million and a median of $18.5 million in 2025 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): plummeted 90.0% in 2022 and later rose 8.54% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $170.5 million in 2021, then plummeted by 90.0% to $17.0 million in 2022, then rose by 2.06% to $17.4 million in 2023, then increased by 1.64% to $17.7 million in 2024, then increased by 6.52% to $18.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for RIGL at $18.8 million in Q4 2025, $19.2 million in Q3 2025, and $18.2 million in Q2 2025.